Chloroquine and Hydroxychloroquine

Information on chloroquine, hydroxychloroquine, and COVID-19 can be found here:
https://www.cdc.gov/coronavirus/2019-ncov/hcp/therapeutic-options.html

Chloroquine and hydroxychloroquine are FDA-approved drugs used to prevent and treat certain types of malaria. They have a long elimination half-life of 30–45 days, allowing for weekly dosing when used in prevention of malaria, and a short 48-hour treatment course when used to treat malaria. These drugs are generally well tolerated at doses used for malaria but may cause pruritis and exacerbate psoriasis. With frequent dosing, rarely reported adverse events include retinopathy and cardiac arrhythmias (QT prolongation specifically) in those with liver or kidney dysfunction. Exceeding recommended doses of chloroquine and hydroxychloroquine can lead to death, and fatal overdoses have been reported. Hydroxychloroquine is also FDA approved for use in rheumatoid arthritis and systemic lupus erythematosis. These drugs are available by prescription only.